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Based on many clinical and preclinical findings the ‘vigilance regulation model of mania’
postulates that an unstable regulation of wakefulness is a pathogenetic factor in both mania
and Attention Deficit Hyperactivity Disorder (ADHD) and induces hyperactivity and sensation
seeking as an autoregulatory attempt to stabilize wakefulness. Accordingly, stimulant medications
with their vigilance stabilizing properties could have rapid antimanic effects similar to their
beneficial effects in ADHD. The MEMAP study – a multi-center, double-blind, placebo-controlled
and randomized clinical trial (RCT) – assessed the antimanic efficacy and safety of a 2.5-day
treatment with methylphenidate (20–40 mg/day). Of 157 screened patients with acute mania, 42
were randomly assigned to receive 20–40 mg per day of methylphenidate in one or two
applications, or placebo. The primary outcome was the change in Young Mania Rating Scale
(YMRS) sum scores from baseline to day 2.5 in the methylphenidate group compared to the
placebo group. A group sequential design was chosen to justify early RCT termination based on
efficacy or futility at an interim analysis after inclusion of 40 patients. In the interim analysis, the
change from baseline in the YMRS total score at day 2.5 was not significantly different between
both groups (F(1,37)=0.23; p=0.64). Thus, futility was declared for methylphenidate and the RCT
was stopped. In summary, although methylphenidate was well tolerated and safe in the full
analysis set, it failed to show efficacy in the treatment of acute mania. Trial registration:
clinicaltrials.gov (URL: http://www.clinicaltrials.gov; registration number: NCT01541605).
& 2017 Elsevier B.V. and ECNP. All rights reserved.
1. Introduction
Treatment response of patients with acute mania with anti-
psychotic agents, benzodiazepines or lithium often requires
high dosages and occurs with a delay of several days (Goikolea
et al., 2013; Grande et al., 2016). Recently the ‘vigilance
regulation model of mania’ has been proposed which suggests
that stimulant medications could be a treatment option
similar to their beneficial effects in ADHD (Hegerl et al.,
2009; Hegerl and Hensch, 2014). This model is based on a
variety of clinical as well as preclinical findings which suggest
that an unstable regulation of vigilance (vigilance=“brain
arousal") is an important pathogenetic factor not only in ADHD
but also in mania. Manic symptoms are interpreted as an
autoregulatory attempt of the organism to stabilize vigilance
by creating a stimulating environment (Hegerl and Hensch,
2014). Indeed, our research group and others have found
unstable vigilance regulation with rapid transitions to EEG
drowsiness patterns and sleep stages in mania (Van Sweden,
1986; Ulrich, 1994; Small et al., 1999; Schönknecht et al.,
2010). Furthermore, destabilizing vigilance (e.g. by sleep
deficits or therapeutic sleep deprivation) can trigger mania
in vulnerable subjects (Wu and Bunney, 1990; Plante and
Winkelman, 2008; for further references see Hegerl and
Hensch, 2014); in contrast, stabilizing vigilance (e.g. by
prolonged sleep) could be shown to have antimanic effects
(e.g., Frank et al., 2005). In line with this concept antimanic
effects of stimulant medications have been reported in several
case reports and case series (e.g., Beckmann and Heinemann,
1976; Garvey et al., 1987; Schönknecht et al., 2010; for
review see Hegerl et al., 2009 as well as Hegerl and Hensch,
2014). A pilot study (Bschor et al., 2001) even demonstrated
reduction of manic symptoms already two hours after onset of
treatment with methylphenidate in a patient with acute
mania and unstable vigilance regulation (for further argu-
ments for antimanic effects of stimulant medications see
Hegerl and Hensch, 2014).
In view of this background, the MEMAP study (Kluge
et al., 2013), a RCT was designed to assess the efficacy
and safety of short-term treatment with methylphenidate in
patients with acute mania.
The primary aim of the RCT was to test the hypothesis
that a 2.5 day treatment with methylphenidate immediate
release given twice daily has better antimanic effects
measured with the Young Mania Rating Scale (YMRS, primary
outcome) (Young et al., 1978) than placebo. It was further
analysed whether instability of vigilance at baseline pre-
dicts response to methylphenidate.
2. Experimental procedures
2.1. Study design overview
Details of the study design have been published elsewhere (Kluge
et al., 2013). In short, the MEMAP study is an exploratory,
randomized, double-blind, placebo-controlled, international
multi-center phase IIIb RCT. It has been designed to assess the
efficacy and safety of the stimulant medication drug methylphe-
nidate (Medikinets) in the initial 2.5 day treatment of acute
mania in patients suffering from bipolar affective disorders. The
primary comparison in this RCT was between methylphenidate
immediate release given twice daily per os (15 mg at 10 a.m. and
3 p.m. on the first day of treatment (day 1), 20 mg at 9 a.m. and
3 p.m. on day 2 and 20 mg at 9 a.m. on day 3) and placebo (also
given twice daily). The lower dose of methylphenidate on day
3 was due to the restriction of treatment duration to 2.5 days and
thus a single application at 9 a.m. The patients got the drug only
U. Hegerl et al.2
Please cite this article as: Hegerl, U., et al., A multi-centre, randomised, double-blind, placebo-controlled clinical trial of
methylphenidate in the initial.... European Neuropsychopharmacology (2017), https://doi.org/10.1016/j.euroneuro.2017.11.003

